WASHINGTON, DC—TRICARE announced that it has added coverage for an enhanced cervical cancer screening test that helps detect the presence of the human papillomavirus (HPV).
“The addition of HPV DNA testing increases the chance that a woman’s health care team will discover a cervical cancer early,” said TRICARE Deputy Director Rear. Adm. Christine Hunter. “Early detection allows prompt treatment and improves survival.”
The HPV DNA test is covered as a cervical cancer screening under TRICARE’s clinical preventive services when performed in conjunction with a Pap smear for women aged 30 and older.
In addition, TRICARE covers the CDC recommended vaccine series to prevent HPV infection in girls. The HPV vaccine is recommended for girls 11 or 12 years of age, but doctors may start the series in girls as young as 9 years old, and can give catch-up vaccinations through 26 years of age for those who have not completed the vaccine series.
SALT LAKE CITY — The presence of deletion 17p (del17), determined by chromosome analysis and/or fluorescence in situ hybridization (FISH), is a strong negative prognostic marker in chronic lymphocytic leukemia (CLL), according to a report in the Journal of Clinical Oncology.1
While increased use of stereotactic body radiation might have played a key role in doubling survival rates for early-stage non-small cell lung cancer (NSCLC) among veterans between 2001 and 2010 compared to conventional radiation, a new study confirms that isn’t always the best way to assure longer survival.